Navigation Links
Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
Date:4/6/2009

y sleepy as narcoleptics and that the treatment effect for those on NUVIGIL was the largest we have seen to date. We are pleased that this positive study will allow us to file our first sNDA for an acute use of NUVIGIL."

NUVIGIL was generally well-tolerated in the study. The adverse events reported in this study of acute use are consistent with chronic use in the current NUVIGIL label. The most common adverse events in the study, observed more frequently with NUVIGIL use, included headache, anxiety, nausea, palpitations and fatigue.

Jet lag disorder is an acute circadian rhythm sleep disorder that results from rapid travel across several time zones. This disorder affects approximately 70 million American travelers annually and gradually resolves once a person adjusts to the new local time.

Circadian rhythm sleep disorders are disruptions in a person's internal body clock, which controls sleep patterns. When the internal body clock is disrupted, certain symptoms may develop affecting a person's ability to sleep, stay awake and function normally. Circadian rhythm sleep disorders can be caused by many factors, including shift work, time zone changes and medications.

Cephalon is preparing to launch NUVIGIL, the longer-lasting isomer of modafinil, in the third quarter of 2009. NUVIGIL is not approved for the treatment of jet lag disorder or its associated symptoms. The U.S. Food and Drug Administration-approved prescribing information for NUVIGIL, including bolded warnings, is available at www.NUVIGIL.com.

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of many unique products in four core therapeutic areas: central nervous system, inflammatory diseases, pain and oncology. A member of
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
2. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
3. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
4. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
5. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. Cynosure Announces Presentation of Favorable Results from Post-Marketing Studies of Smartlipo MPX
8. Pharmaxis Announces Milestone in Phase III Trial for Cystic Fibrosis
9. Schering-Plough Announces Results of the Early ACS Trial
10. Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders
11. Lilly Announces Inconclusive Phase II Study Results for mGlu2/3 at the International Congress on Schizophrenia Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... PARK, N.C. , March 31, 2015  Dr. ... will be attending the World Orphan Drug Congress in April ... regulatory approval process and orphan drugs below: ... (DTAB) has recommended to the Ministry of Health that if ... country, marketing authorization can be obtained in India ...
(Date:3/31/2015)...  On May 2, 2015 global experts on ... Santa Monica, CA at the 5th ... Pleural Mesothelioma (MPM), a rare form of cancer ... affects the lining of the chest– the pleura. ... Pacific Mesothelioma Center (PMC). ...
(Date:3/31/2015)... BC , March 31, 2015 /CNW/ - T-Bird Pharma ... focused on developing premium quality medical marijuana products and ... Marihuana for Medical Purposes Regulations ( Canada ... received notice from The Corporation of the District of ... approval of the Company,s premises which now allows for ...
Breaking Medicine Technology:Max Neeman to Discuss India's Orphan Drug Regulations at WOD 2015 2Cutting-Edge Research to Be Presented at 5th Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma in Santa Monica 2Cutting-Edge Research to Be Presented at 5th Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma in Santa Monica 3Cutting-Edge Research to Be Presented at 5th Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma in Santa Monica 4T-Bird Pharma Inc. Announces Final Municipal Rezoning Approval 2T-Bird Pharma Inc. Announces Final Municipal Rezoning Approval 3
... Bionovo, Inc.,(Nasdaq: BNVI ) announced today that its ... Phase 2 clinical testing after the,successful completion of a ... clinical trial was conducted to identify the maximum,tolerated dose ... of the,company,s novel, oral, anticancer treatment. A total of ...
... MedImmune today announced,that it has initiated a Phase ... healthy children one month to 12 months of age ... is,the most common respiratory infection in infants and can ... is a serious respiratory disease that can have significant ...
Cached Medicine Technology:Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer 2Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer 3Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer 4MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine 2
(Date:3/31/2015)... Karen A. Daley, Ph.D. will address graduates ... Commencement ceremony on May 9, 2015 and will ... of her eminent career as a nurse, public health ... and senior staff nurse at Brigham and Women’s Hospital ... roles, including President of the American Nurses Association in ...
(Date:3/31/2015)... Indosoft, developer of the Q-Suite call center software suite, announces ... 5.x line. The industry leading contact center ACD ... for more than a decade. By announcing an end of ... fully embrace newer Asterisk features and improve performance. , Q-Suite ... more than a decade. The use of Asterisk, a free, ...
(Date:3/31/2015)... Clinovo, a leading provider of ... , the premiere voice of Northern California’s Life ... companies. , BayBio brings together the collective ... and productive life science cluster, helping companies grow, ... most pressing challenges. , “We are thrilled ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 Healthpointe’s team ... injuries at all of their clinics. Specialties include hip ... , For athletes with hip injuries, Healthpointe has ... assess and treat the symptoms and underlying causes of ... minimally-invasive care and prevent future damage, while taking into ...
(Date:3/31/2015)... Former 49ers linebacker Chris Borland turned more ... year of a promising NFL career. In a March episode ... Writer Will Leitch explores the curious case of Borland ... the decision making process that Borland and other football players ... a large paycheck, and what impact, if any, he thinks ...
Breaking Medicine News(10 mins):Health News:Rivier University to recognize nurse leader, educator and safety advocate at 80th Commencement on May 9th 2Health News:Rivier University to recognize nurse leader, educator and safety advocate at 80th Commencement on May 9th 3Health News:Indosoft Announces End of Life for Asterisk 1.4 Support in Q-Suite 5 Call Center Software 2Health News:Clinovo Joins BayBio Membership Program, The Leading Life Science Association in Northern California 2Health News:Healthpointe Now Treating Hip Dislocations, Hip Fractures, Hip Bursitis, and Hip Strains at Locations in Southern California 2Health News:Will Leitch and the Curious Case of Chris Borland on SCI TV 2Health News:Will Leitch and the Curious Case of Chris Borland on SCI TV 3
... famous for talking to animals, then here,s a story that ... published online in The FASEB Journal ( http://www.fasebj.org ... subcutaneous adipose (fat) tissue with muscle cells from rat hearts. ... cells altogether, but they actually beat. "Recovery of regenerative ...
... Grafton, Mass., February 28, 2011 Researchers at the Cummings ... an antibody-based treatment for Hemolytic Uremic Syndrome (HUS), a potentially ... leading cause of kidney failure in children. HUS is ... produce Shiga toxins and are responsible for about 100,000 annual ...
... lll. A farmer in Niger learns how to protect ... rural Haitian village learns how to avoid exposure to cholera. ... oil from shea seeds to make shea butter she can ... from a new approach to sustainable development education that reaches ...
... WASHINGTON, February 28, 2011) Results from a study ... American Society of Hematology reveal a close relationship between ... arteries carrying blood from the heart to the lungsand ... (known as myeloid abnormalities). The study, which was ...
... in breast cancer incidence rates among non-Hispanic white women ... use of postmenopausal hormone therapy did not continue through ... Cancer Society and the National Cancer Institute. While there ... may indicate that the decrease in breast cancers thought ...
... (HealthDay News) -- A new study finds that heart attack ... other heart attack patients to receive priority care at emergency ... patients admitted to 96 hospitals in the province of Ontario ... had a history of depression recorded in their medical charts. ...
Cached Medicine News:Health News:Human stem cells from fat tissue fuse with rat heart cells and beat 2Health News:Tufts receives patent for antibody treatment against hemolytic uremic syndrome 2Health News:Team delivers development aid via cell phone animations 2Health News:Team delivers development aid via cell phone animations 3Health News:Study finds close linkage between a rare, deadly lung condition and blood cell abnormalities 2Health News:Study finds breast cancer incidence rates no longer declining in US women 2Health News:Heart Patients With Depression Often Find ER Delays 2
... valve is enclosed in a ... the valve from being accidentally ... or reclining positions. The valve ... free ensuring uninterrupted flow and ...
Intermittent catheter - Ready-to-Use Sterile, Enclosed System...
... The VerifyNow (Ultegra) System is ... which measures platelet induced aggregation as ... system consists of an instrument, a ... assay device contains reagents based on ...
... The Model 700 Whole Blood/Optical Lumi-Aggregometer available ... This new Aggregometer measures platelet function on ... blood or optical density in plasma with ... method. The Model 700 Aggregometer also has ...
Medicine Products: